DelveInsight’s, “Asthma Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Asthma Research. Learn more about our innovative pipeline today! @ Asthma Pipeline Outlook
Key Takeaways from the Asthma Pipeline Report
- In October 2024:- Macleods Pharmaceuticals- A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (Distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients With Stable Mild Asthma
- In October 2024:- Chiesi Farmaceutici S.p.A- A 12 Week, Randomized, Double-blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compared to CHF 718 pMDI 800µg Total Daily Dose (Extrafine Beclomethasone Dipropionate) in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
- In October 2024:- Regeneron Pharmaceuticals- The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA.
- In October 2024:- Teva Branded Pharmaceutical- A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma. The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 35 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria.
- In October 2024:- Sanofi- This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.
- In October 2024:- Amgen- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma. The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
- In October 2024:- AstraZeneca- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants With Asthma.
- In October 2024:- Haisco Pharmaceutical Group Co., Ltd.- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma. This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma.
- DelveInsight’s Asthma pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Asthma treatment.
- The leading Asthma Companies such as GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.
- Promising Asthma Therapies such as HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.
Stay informed about the cutting-edge advancements in Asthma treatments. Download for updates and be a part of the revolution in care @ Asthma Clinical Trials Assessment
Asthma Emerging Drugs Profile
- GSK3511294: GlaxoSmithKline
GSK’294 is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. In patients with severe eosinophilic asthma, targeted anti-IL-5 therapies are a well-established and effective treatment approach. GSK3511294 is currently being investigated in Phase III stage of Clinical trial evaluation for the treatment of Asthma.
- TQC2731: Chia Tai Tianqing Pharmaceutical Group
TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
- AZD4604: AstraZeneca
AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
- FB704A: Oneness Biotech Co., Ltd.
FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. FB704A (anti-IL-6 Ab) can reduce bronchial hyperresponsiveness as well as the Th1, Th2, and Th17 inflammatory responses of the respiratory tract, inhibit IL-6 classic- and trans-signaling pathways, and therefore have a chance of improving the symptoms of severe asthma (with high neutrophils) and severe mixed-granulocytic asthma. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
- ARO-RAGE: Arrowhead Pharmaceuticals
ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases. It is currently being investigated in Phase I stage of Clinical trial evaluation for the treatment of Asthma.
Learn more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ Asthma Unmet Needs
Asthma Companies
GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.
Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Asthma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover the latest advancements in Asthma treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Asthma Market Drivers and Barriers, and Future Perspectives
Scope of the Asthma Pipeline Report
- Coverage- Global
- Asthma Companies- GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.
- Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.
- Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Asthma Pipeline on our website @ Asthma Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Asthma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Asthma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- GSK3511294: GlaxoSmithKline
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TQC2731: Chia Tai Tianqing Pharmaceutical Group
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ARO-RAGE: Arrowhead Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Asthma Key Companies
- Asthma Key Products
- Asthma- Unmet Needs
- Asthma- Market Drivers and Barriers
- Asthma- Future Perspectives and Conclusion
- Asthma Analyst Views
- Asthma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/